Matthew Sterling

Matthew Sterling
Dr. Sterling graduated with high distinction from the Schreyer Honors College at Penn State University and then obtained his medical degree from Rutgers-Robert Wood Johnson Medical School. He completed his general surgery internship and urology residency at the University of Pennsylvania Health System, including the Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia. He then completed a fellowship in genitourinary trauma and reconstructive urology at Temple University Hospital. Dr. Sterling is one of only a few urologists in the greater Philadelphia area to have specific fellowship training in reconstructive urology and prosthetics. Dr. Sterling is a member of the American Urologic Association and has been inducted into the Alpha Omega Alpha National Medical Honor Society and the Arnold P. Gold Humanism Honor Society. While he practices all aspects of general urology, his clinical and research interests include: men’s health, BPH and minimally invasive surgery for prostatic enlargement, erectile dysfunction including penile implant surgery, minimally invasive treatment for Peyronie’s disease, urethral stricture disease, voiding dysfunction/urodynamics, urinary incontinence/leakage, and kidney stone disease.
Medical School:

Rutgers-Robert Wood Johnson Medical School

Residency:

Urology Residency - Hospital of the University of Pennsylvania

Fellowship:

Genitourinary trauma and reconstructive urology fellowship - Temple University Hospital

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only